Evidence map›Paper›PMID 42322431›Full record

ArticleCancer immunology, immunotherapy : CII2026

Oncolytic virus with an immune stimulatory payload for osteosarcoma therapy.

Sumbul Khan, Theresa A Higgins, Isabella Shimko-Lofano, Maninder Sandey, Emma Logsdon, Gracie Bunch, Yasin Fatemi, Leah M K Hoffman, Bruce F Smith, Payal Agarwal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Sumbul Khan *Scott Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, AL, USA.
Theresa A HigginsScott Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, AL, USA.
Isabella Shimko-LofanoScott Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, AL, USA.
Maninder SandeyScott Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, AL, USA.
Emma LogsdonScott Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, AL, USA.
Gracie BunchScott Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, AL, USA.
Yasin FatemiDepartment of Mathematics and Statistics, College of Sciences and Mathematics, Auburn University, Auburn, AL, USA.
Leah M K HoffmanScott Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, AL, USA.
Bruce F SmithScott Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, AL, USA.
Payal AgarwalScott Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, AL, USA. agarwpa@auburn.edu.

Funding

Exploration of different immunotherapy modalities in osteosarcomaR15CA283777 · NCI · AUBURN UNIVERSITY AT AUBURN · PI AGARWAL, PAYAL · 2023 to 2023
$441k
NCI NIH HHS R15 CA283777NIH NCI R15 CA283777-01
6 · The paper itself

Abstract

Osteosarcoma (OS) is a highly aggressive bone malignancy that predominantly affects children and young adults. There have been no major changes in patient survival in the past four decades. Therefore, new therapeutic interventions are needed. We have developed an enhanced conditionally replicative canine oncolytic adenovirus, CAV2-AU-M3, armed with an anti-PD1 heavy-chain antibody (HcAb), and evaluated its efficacy against osteosarcoma across four canine cell lines. CAV2-AU-M3 was characterized for its infectivity, lytic properties, and anti-PD1 Ab production in monolayer and spheroid cultures. Additionally, the impact of intratumoral administration of the virus on tumor growth was measured in a mouse model. Our study demonstrates that CAV2-AU-M3 infects and lyses different canine OS cell lines at varying rates but produces anti-PD1 Ab at similar levels across all osteosarcoma cell lines. Additionally, anti-PD1 Ab produced by CAV2-AU-M3 can effectively bind the cell surface PD1 receptor and inhibit the binding of PDL1 to PD1 receptors.

Indexed as

Adenoviruses, CanineBone NeoplasmsOncolytic VirotherapyOncolytic VirusesOsteosarcomaAnimalsCell Line, TumorDogsHumansMiceProgrammed Cell Death 1 ReceptorProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsOncolytic VirusesOsteosarcomaTumor MicroenvironmentTumor Spheroids

Identifiers

PMID42322431
PMCPMC13578186

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.